These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 34752803)
41. Nasal sprays for treating COVID-19: a scientific note. Chavda VP; Baviskar KP; Vaghela DA; Raut SS; Bedse AP Pharmacol Rep; 2023 Apr; 75(2):249-265. PubMed ID: 36848033 [TBL] [Abstract][Full Text] [Related]
42. Virucidal Properties of Molecular Iodine Oral Rinse Against SARS-CoV-2. Teagle V; Clem DS; Yoon T Compend Contin Educ Dent; 2022 Feb; 43(2):e13-e16. PubMed ID: 35148480 [TBL] [Abstract][Full Text] [Related]
43. A sprayable Acid-Oxidizing solution containing hypochlorous acid (AOS2020) efficiently and safely inactivates SARS-Cov-2: a new potential solution for upper respiratory tract hygiene. Giarratana N; Rajan B; Kamala K; Mendenhall M; Reiner G Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3099-3103. PubMed ID: 33575830 [TBL] [Abstract][Full Text] [Related]
44. COVID-19 manifestation in the oral cavity - a narrative literature review. Kusiak A; Cichońska D; Tubaja M; Skorek A; Jereczek-Fossa BA; Corrao G; Marvaso G; Alterio D Acta Otorhinolaryngol Ital; 2021 Oct; 41(5):395-400. PubMed ID: 34734574 [TBL] [Abstract][Full Text] [Related]
45. Computational optimization of delivery parameters to guide the development of targeted Nasal spray. Du J; Shao X; Bouteiller JC; Lu A; Asante I; Louie S; Humayun MS; Lazzi G Sci Rep; 2023 Mar; 13(1):4099. PubMed ID: 36907909 [TBL] [Abstract][Full Text] [Related]
46. Letter to the editor regarding "The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients". Verma RR; Gupta N; Singh M Am J Otolaryngol; 2021; 42(5):103103. PubMed ID: 34116850 [No Abstract] [Full Text] [Related]
47. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in taste dysgeusia in COVID-19 patients. Singh CV; Jain S; Parveen S; Deshmukh P Am J Otolaryngol; 2021; 42(4):103009. PubMed ID: 33846030 [No Abstract] [Full Text] [Related]
48. Does Trypsin Oral Spray (Viruprotect Huijghebaert S; Vanham G; Van Winckel M; Allegaert K Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34064793 [TBL] [Abstract][Full Text] [Related]
49. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19. Baker N; Williams AJ; Tropsha A; Ekins S Pharm Res; 2020 May; 37(6):104. PubMed ID: 32451736 [TBL] [Abstract][Full Text] [Related]
50. In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens. Eggers M; Koburger-Janssen T; Eickmann M; Zorn J Infect Dis Ther; 2018 Jun; 7(2):249-259. PubMed ID: 29633177 [TBL] [Abstract][Full Text] [Related]
51. Using nasal sprays to prevent respiratory tract infections: a qualitative study of online consumer reviews and primary care patient interviews. Williamson S; Dennison L; Greenwell K; Denison-Day J; Mowbray F; Richards-Hall S; Smith D; Bradbury K; Ainsworth B; Little P; Geraghty AWA; Yardley L BMJ Open; 2022 Jun; 12(6):e059661. PubMed ID: 35772824 [TBL] [Abstract][Full Text] [Related]
52. Interferon-α-2b Nasal Spray for Treating SARS-CoV-2 Omicron Variant-Infected Children. Zhou J; Chen X; Lu Y; Wang L; Yu H J Clin Immunol; 2023 Jul; 43(5):862-864. PubMed ID: 36809596 [No Abstract] [Full Text] [Related]
53. Society of swallowing and dysphagia of Japan: Position statement on dysphagia management during the COVID-19 outbreak. Kimura Y; Ueha R; Furukawa T; Oshima F; Fujitani J; Nakajima J; Kaneoka A; Aoyama H; Fujimoto Y; Umezaki T Auris Nasus Larynx; 2020 Oct; 47(5):715-726. PubMed ID: 32736887 [TBL] [Abstract][Full Text] [Related]
54. The interest of fluticasone nasal spray in COVID-19 related anosmia is still not demonstrated. Lechien JR; Hoch CC; Vaira LA; Saussez S Am J Otolaryngol; 2021; 42(4):103008. PubMed ID: 33810883 [No Abstract] [Full Text] [Related]
55. Is the oral cavity relevant in SARS-CoV-2 pandemic? Herrera D; Serrano J; Roldán S; Sanz M Clin Oral Investig; 2020 Aug; 24(8):2925-2930. PubMed ID: 32577830 [TBL] [Abstract][Full Text] [Related]
56. Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro. Muñoz-Basagoiti J; Perez-Zsolt D; León R; Blanc V; Raïch-Regué D; Cano-Sarabia M; Trinité B; Pradenas E; Blanco J; Gispert J; Clotet B; Izquierdo-Useros N J Dent Res; 2021 Oct; 100(11):1265-1272. PubMed ID: 34282982 [TBL] [Abstract][Full Text] [Related]
57. Epidemiology and precision of SARS-CoV-2 detection following lockdown and relaxation measures. Leuzinger K; Gosert R; Søgaard KK; Naegele K; Bielicki J; Roloff T; Bingisser R; Nickel CH; Khanna N; Sutter ST; Widmer AF; Rentsch K; Pargger H; Siegemund M; Stolz D; Tamm M; Bassetti S; Osthoff M; Battegay M; Egli A; Hirsch HH J Med Virol; 2021 Apr; 93(4):2374-2384. PubMed ID: 33314153 [TBL] [Abstract][Full Text] [Related]
58. The Contribution of Galenics to Patients' Sensory Perception of Nasal Sprays After Nasal Surgery: Data from a Prospective Randomised, Controlled, Double-Blind, Crossover, Multicentre Study. Bergmann C; Lander J; Radtke L; England L; Singh J; Mösges R Adv Ther; 2021 Dec; 38(12):5829-5843. PubMed ID: 34689304 [TBL] [Abstract][Full Text] [Related]
59. SARS-CoV-2 Infection and Significance of Oral Health Management in the Era of "the New Normal with COVID-19". Imai K; Tanaka H Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207046 [TBL] [Abstract][Full Text] [Related]
60. Can povidone iodine gargle/mouthrinse inactivate SARS-CoV-2 and decrease the risk of nosocomial and community transmission during the COVID-19 pandemic? An evidence-based update. Chopra A; Sivaraman K; Radhakrishnan R; Balakrishnan D; Narayana A Jpn Dent Sci Rev; 2021 Nov; 57():39-45. PubMed ID: 33747261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]